Current oncology最新文献_第9页

Failure Modes in Orthopedic Oncologic Reconstructive Surgery: A Review of Imaging Findings and Failure Rates. 骨科肿瘤整形手术的失败模式：成像结果和失败率回顾。

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-17 DOI: 10.3390/curroncol31100465

Anuj Shah, Fabiano N Cardoso, Felipe Souza, Julien Montreuil, Juan Pretell-Mazzini, H Thomas Temple, Francis Hornicek, Brooke Crawford, Ty K Subhawong

{"title":"Failure Modes in Orthopedic Oncologic Reconstructive Surgery: A Review of Imaging Findings and Failure Rates.","authors":"Anuj Shah, Fabiano N Cardoso, Felipe Souza, Julien Montreuil, Juan Pretell-Mazzini, H Thomas Temple, Francis Hornicek, Brooke Crawford, Ty K Subhawong","doi":"10.3390/curroncol31100465","DOIUrl":"https://doi.org/10.3390/curroncol31100465","url":null,"abstract":"Limb salvage surgeries utilizing endoprostheses and allografts are performed for a variety of oncologic conditions. These reconstructions can fail and require revision for many reasons, which are outlined and classified into mechanical failures (soft tissue failures, aseptic loosening, structural failure), non-mechanical failures (infection, tumor progression), and pediatric failures (physeal arrest, growth dysplasia). Distinct radiologic and clinical findings define specific failure subtypes but are sparsely illustrated in the radiology literature. Specifically, an understanding of the organizational structure of the failure modes can direct radiologists' search for post-reconstruction complications, enhance an appreciation of their prognostic significance, and facilitate research by standardizing the language and conceptual framework around outcomes. The purpose of this review is to highlight the key radiologic findings and imaging studies of each failure mode in orthopedic oncologic reconstructive surgery in the context of risk factors, failure rates, prognosis and survival statistics, and clinical decision-making regarding chemotherapy, radiation, and revision surgery.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6245-6266"},"PeriodicalIF":2.8,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

No Impact of COVID-19 Pandemic on Early Mortality for Thyroid Cancer in the US. Comment on Lee et al. Impact of the COVID-19 Pandemic on Thyroid Cancer Surgery. Curr. Oncol. 2024, 31, 3579-3590. COVID-19大流行对美国甲状腺癌早期死亡率没有影响。评论 Lee 等：《COVID-19 大流行对甲状腺癌手术的影响》。Curr.Oncol.2024, 31, 3579-3590.

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-17 DOI: 10.3390/curroncol31100466

Riccardo Nocini, Giuseppe Lippi, Camilla Mattiuzzi

引用次数: 0

Timely Treatment and No Change in Thyroid Cancer Mortality During COVID-19 Pandemic. Reply to Nocini et al. No Impact of COVID-19 Pandemic on Early Mortality for Thyroid Cancer in the US. Comment on "Lee et al. Impact of the COVID-19 Pandemic on Thyroid Cancer Surgery. Curr. Oncol. 2024, 31, 3579-3590". COVID-19大流行期间及时治疗和甲状腺癌死亡率无变化。回复 Nocini 等：《COVID-19 大流行对美国甲状腺癌早期死亡率无影响》。对 "Lee等：COVID-19大流行对甲状腺癌手术的影响 "的评论。Curr.Oncol.2024, 31, 3579-3590".

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-17 DOI: 10.3390/curroncol31100467

Max L Lee, Michelle M Chen

引用次数: 0

Enhancing Thoracic Surgery with AI: A Review of Current Practices and Emerging Trends. 利用人工智能改进胸外科手术：当前实践与新兴趋势回顾。

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-17 DOI: 10.3390/curroncol31100464

Mohamed Umair Aleem, Jibran Ahmad Khan, Asser Younes, Belal Nedal Sabbah, Waleed Saleh, Marcello Migliore

引用次数: 0

Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care. 2023 年加拿大全国胰腺会议：多学科参与胰腺癌治疗回顾。

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-16 DOI: 10.3390/curroncol31100461

Jessica L Nickerson, Chloe Cyr, Riley J Arseneau, Stacey N Lee, Stefanie Condon-Oldreive, George Zogopoulos, Keith Roberts, Christina A Kim, Sylvia S W Ng, Masoom Haider, Eva Villalba, Leah Stephenson, Erica Tsang, Brent Johnston, Boris Gala-Lopez, Valerie Cooper, Breffni Hannon, Anne Gangloff, Sharlene Gill, Filomena Servidio-Italiano, Ravi Ramjeesingh

{"title":"Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care.","authors":"Jessica L Nickerson, Chloe Cyr, Riley J Arseneau, Stacey N Lee, Stefanie Condon-Oldreive, George Zogopoulos, Keith Roberts, Christina A Kim, Sylvia S W Ng, Masoom Haider, Eva Villalba, Leah Stephenson, Erica Tsang, Brent Johnston, Boris Gala-Lopez, Valerie Cooper, Breffni Hannon, Anne Gangloff, Sharlene Gill, Filomena Servidio-Italiano, Ravi Ramjeesingh","doi":"10.3390/curroncol31100461","DOIUrl":"10.3390/curroncol31100461","url":null,"abstract":"Pancreatic cancer is a complex malignancy associated with poor prognosis and high symptom burden. Optimal patient care relies on the integration of various sectors in the healthcare field as well as innovation through research. The Canadian National Pancreas Conference (NPC) was co-organized and hosted by Craig's Cause Pancreatic Cancer Society and The Royal College of Physicians and Surgeons in November 2023 in Montreal, Canada. The conference sought to bridge the gap between Canadian healthcare providers and researchers who share the common goal of improving the prognosis, quality of life, and survival for patients with pancreatic cancer. The accredited event featured discussion topics including diagnosis and screening, value-based and palliative care, pancreatic enzyme replacement therapy, cancer-reducing treatment, and an overview of the current management landscape. The present article reviews the NPC sessions and discusses the presented content with respect to the current literature.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6191-6204"},"PeriodicalIF":2.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response. 接受阿特珠单抗/贝伐单抗联合疗法并获得完全应答的晚期肝细胞癌患者的特征和预后

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-16 DOI: 10.3390/curroncol31100463

Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yoshihiko Tachi, Takeshi Ukai, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka

{"title":"Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.","authors":"Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yoshihiko Tachi, Takeshi Ukai, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka","doi":"10.3390/curroncol31100463","DOIUrl":"https://doi.org/10.3390/curroncol31100463","url":null,"abstract":"Aim: To investigate the characteristics and prognosis of patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab and bevacizumab (Atz/Bev) who achieved a complete response (CR) according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST).Methods: A total of 120 patients with Eastern Cooperative Oncology Group performance status (PS) 0 or 1 and Child-Pugh A at the start of Atz/Bev treatment were included. Barcelona Clinic Liver Cancer stage C was recorded in 59 patients.Results: The CR rate with Atz/Bev alone was 15.0%. The median time to CR was 3.4 months, and the median duration of CR was 15.6 months. A significant factor associated with achieving CR with Atz/Bev alone was an AFP ratio of 0.34 or less at 3 weeks. Adding transarterial chemoembolization (TACE) in the six patients who achieved a partial response increased the overall CR rate to 20%. Among the 24 patients who achieved CR, the median progression-free survival was 19.3 months, the median overall survival was not reached, and 14 patients (58.3%) were able to discontinue Atz/Bev and achieve a drug-free status. Twelve of these patients developed progressive disease (PD), but eleven successfully received post-PD treatments and responded well.Conclusions: Achieving CR by mRECIST using Atz/Bev alone or with additional TACE can be expected to offer an extremely favorable prognosis.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6218-6231"},"PeriodicalIF":2.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in Health Care Expenditures by Cancer Patients During Their Last Year of Life: A Registry-Based Study. 癌症患者在生命最后一年的医疗支出差异：基于登记册的研究。

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-16 DOI: 10.3390/curroncol31100462

Peter Strang, Max Petzold, Linda Björkhem-Bergman, Torbjörn Schultz

{"title":"Differences in Health Care Expenditures by Cancer Patients During Their Last Year of Life: A Registry-Based Study.","authors":"Peter Strang, Max Petzold, Linda Björkhem-Bergman, Torbjörn Schultz","doi":"10.3390/curroncol31100462","DOIUrl":"https://doi.org/10.3390/curroncol31100462","url":null,"abstract":"Background: During the last year of life, persons with cancer should probably have similar care needs and costs, but studies suggest otherwise.Methods: A study of direct medical costs (excluding costs for expensive prescription drugs) was performed based on registry data in Stockholm County, which covers 2.4 million inhabitants, for all deceased persons with cancer during 2015-2021. The data were mainly analyzed with the aid of multiple regression models, including Generalized Linear Models (GLMs).Results: In a population of 20,431 deceased persons with cancer, the costs increased month by month (p < 0.0001). Higher costs were mainly associated with lower age (p < 0.0001), higher risk of frailty, as measured by the Hospital Frailty Risk Scale (p < 0.0001), and having a hematological malignancy. In a separate model, where those 5% with the highest costs were identified, these variables were strengthened. Sex and socio-economic groups on an area level had little or no significance. Systemic cancer treatments during the last month of life and acute hospitals as place of death had only a moderate impact on costs in adjusted models.Conclusions: Higher costs are mainly related to lower age, higher frailty risk and having a hematological malignancy, and the effects are both statistically and clinically significant despite the fact that expensive drugs were not included. On the other hand, the costs were mainly comparable in regard to sex or socio-economic factors, indicating equal care.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6205-6217"},"PeriodicalIF":2.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-14 DOI: 10.3390/curroncol31100459

Anna Fischl, Michael Gerken, Patricia Lindberg-Scharf, Tareq M Haedenkamp, Katharina Rosengarth, Andrea Hillberg, Martin Vogelhuber, Ingrid Schön, Martin Proescholdt, Tommaso Araceli, Michael Koller, Anne Herrmann, Oliver Kölbl, Tobias Pukrop, Markus J Riemenschneider, Nils Ole Schmidt, Monika Klinkhammer-Schalke, Ralf Linker, Peter Hau, Elisabeth Bumes

{"title":"Health-Related Quality of Life and Treatment Satisfaction of Patients with Malignant IDH Wild-Type Gliomas and Their Caregivers.","authors":"Anna Fischl, Michael Gerken, Patricia Lindberg-Scharf, Tareq M Haedenkamp, Katharina Rosengarth, Andrea Hillberg, Martin Vogelhuber, Ingrid Schön, Martin Proescholdt, Tommaso Araceli, Michael Koller, Anne Herrmann, Oliver Kölbl, Tobias Pukrop, Markus J Riemenschneider, Nils Ole Schmidt, Monika Klinkhammer-Schalke, Ralf Linker, Peter Hau, Elisabeth Bumes","doi":"10.3390/curroncol31100459","DOIUrl":"https://doi.org/10.3390/curroncol31100459","url":null,"abstract":"(1) Background: Clinical aspects like sex, age, Karnofsky Performance Scale (KPS) and psychosocial distress can affect the health-related quality of life (HR-QoL) and treatment satisfaction of patients with malignant isocitrate dehydrogenase wild-type (IDHwt) gliomas and caregivers. (2) Methods: We prospectively investigated the HR-QoL and patient/caregiver treatment satisfaction in a cross-sectional study with univariable and multiple regression analyses. Questionnaires were applied to investigate the HR-QoL (EORTC QLQ-C30, QLQ-BN20) and treatment satisfaction (EORTC PATSAT-C33). (3) Results: A cohort of 61 patients was investigated. A higher KPS was significantly associated with a better HR-QoL regarding the functional scales of the EORTC QLQ-C30 (p < 0.004) and a lower symptom burden regarding the EORTC QLQ-BN20 (p < 0.001). The patient treatment satisfaction was significantly poorer in the patients older than 60 years in the domain of family involvement (p = 0.010). None of the investigated aspects showed a significant impact on the treatment satisfaction of caregivers. (4) Conclusions: We demonstrated that in patients with IDHwt gliomas, the KPS was the most important predictor for a better HR-QoL in functional domains. Data on the HR-QoL and treatment satisfaction in patients with IDHwt gliomas and their caregivers are rare; therefore, further efforts should be made to improve supportive care in this highly distressed cohort.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6155-6170"},"PeriodicalIF":2.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506037/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient-Reported Outcomes after Surgical, Endoscopic, or Radiological Techniques for Nutritional Support in Esophageal Cancer Patients: A Systematic Review. 食管癌患者采用手术、内窥镜或放射技术进行营养支持后的患者报告结果：系统回顾

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-14 DOI: 10.3390/curroncol31100460

Filipa Fontes, Davide Fernandes, Ana Almeida, Inês Sá, Mário Dinis-Ribeiro

{"title":"Patient-Reported Outcomes after Surgical, Endoscopic, or Radiological Techniques for Nutritional Support in Esophageal Cancer Patients: A Systematic Review.","authors":"Filipa Fontes, Davide Fernandes, Ana Almeida, Inês Sá, Mário Dinis-Ribeiro","doi":"10.3390/curroncol31100460","DOIUrl":"10.3390/curroncol31100460","url":null,"abstract":"Several techniques exist to maintain oral and/or enteral feeding among esophageal cancer (EC) patients, but their impact on patient-reported outcomes (PROs) remains unclear. This systematic review aimed to assess the impact of nutritional support techniques on PROs in EC patients. We searched Medline, Web of Science, and CINAHL Complete from inception to 3 April 2024. Eligible studies included those evaluating EC patients, reporting PROs using standardized measures, and providing data on different nutritional support techniques or comparing them to no intervention. The reference lists of the included studies were also screened for additional eligible articles. The Mixed Methods Appraisal Tool was used to evaluate the quality of the included studies. Of the 694 articles identified from databases and 224 from backward citation, 11 studies met the inclusion criteria. Nine studies evaluated the overall quality of life (QoL), four assessed pain, and one evaluated depression. Among those submitted to esophagectomy, jejunostomy may be associated with higher QoL scores and less postoperative pain, compared to a nasojejunal tube, but no significant differences were found when compared to no intervention. For patients undergoing chemotherapy or receiving palliative/symptomatic treatment, expandable metal stents (SEMSs) were associated with higher levels of emotional functioning when compared with laparoscopic gastrostomy. Moreover, percutaneous endoscopic gastrostomy or SEMSs were associated with a higher QoL compared with nasogastric tubes. This review underscores the importance of considering PRO measures when evaluating nutritional support techniques in cancer patients, though further robust evidence is needed to fully understand these associations.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6171-6190"},"PeriodicalIF":2.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11505681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors Associated with Multimodal Care Practices for Cancer Cachexia among Pharmacists. 与药剂师对癌症疼痛的多模式护理实践相关的因素。

IF 2.8 4区医学

Current oncology Pub Date : 2024-10-12 DOI: 10.3390/curroncol31100457

Satomi Okamura, Koji Amano, Saori Koshimoto, Sayaka Arakawa, Hiroto Ishiki, Eriko Satomi, Tatsuya Morita, Takashi Takeuchi, Naoharu Mori, Tomomi Yamada

{"title":"Factors Associated with Multimodal Care Practices for Cancer Cachexia among Pharmacists.","authors":"Satomi Okamura, Koji Amano, Saori Koshimoto, Sayaka Arakawa, Hiroto Ishiki, Eriko Satomi, Tatsuya Morita, Takashi Takeuchi, Naoharu Mori, Tomomi Yamada","doi":"10.3390/curroncol31100457","DOIUrl":"https://doi.org/10.3390/curroncol31100457","url":null,"abstract":"Pharmacists' roles in cachexia care are unclear. This study aimed to clarify the knowledge and practice of cachexia care and identify factors related to the practice of cachexia care among pharmacists. Information on the knowledge and practice of cachexia care was obtained. Components of practicing multimodal care were evaluated. Participants were categorized into two groups according to practicing multimodal care levels. Comparisons were made between the groups, and multiple regression analysis was employed. Of the 451 pharmacists, 243 responded. They were categorized into the Practicing group (n = 119) and Not practicing group (n = 124). Significant differences were observed for the number of advanced cancer patients/month, frequency of caring for them, and involvement in training programs on cachexia. The Practicing group had significantly better knowledge about cachexia. The Practicing group used guidelines, items, and symptoms more frequently to detect cachexia. The Practicing group tended to detect cachexia and initiate interventions in earlier phases and in patients with a better status. Multivariate logistic regression analysis showed that the most significant factor was the regular provision of care (odds ratio, 2.07; 95% confidence interval, 1.10-3.92). The regular provision of care was associated with the practice of multimodal care.","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 10","pages":"6133-6143"},"PeriodicalIF":2.8,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0